Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q1- Text added to 2022 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
aluminosilicate, bifurcated, broader, category, certiorari, CHMP, Committee, compatibility, Concurrently, construct, evidence, FL, highest, inhibitory, lifted, MiroBio, multidrug, NCCN, Network, notice, opinion, oxygen, pneumonia, preferred, regimen, resubmission, resubmitted, sacituzumab, smaller, storage, unchanged, understand, uniform, vial
Removed:
absorb, allocating, Australia, Australian, beneficiary, Canadian, canceled, CFCA, CODM, compound, comprised, customer, deploy, disaggregated, diversification, dolutegravir, employment, entitled, equal, excluding, external, France, funding, inception, integrase, intercompany, invested, Japanese, Korea, Korean, liable, Managing, noncontrolling, originally, outbreak, portfolio, preservation, principally, priority, prompt, reallocate, relate, retained, Shionogi, significance, structurally, taxing, type, unmet, variable, VIE
Valuein 2022 Q1 filing- Value in 2022 Q2 filing
Original filings
Filing view